The subject invention pertains to novel compounds (and salts thereof), and compositions
comprising the compounds, for the treatment of cardiac arrhythmias. The subject
invention further concerns methods of making the novel compounds. The novel compounds
are rapidly metabolized analogs of amiodarone, having the distinct and advantageous
characteristic of being metabolized to a less lipophilic compound. This results
in an improved safety profile. The new compounds have particular utility for treating
life-threatening ventricular tachyarrhythmias, especially in patients with congestive
heart failure (CHF). The compounds also provide effective management for ventricular
arrhythmias and supraventricular arrhythmias, including atrial fibrillation and
re-entrant tachyarrhythmias involving accessory pathways.